Autologous bone marrow stem cell transplantation for the treatment of type 2 diabetes mellitus

Chinese Medical Journal

Volumn 124, Issue 22, 2011, Pages 3622-3628

  Wang, Li ^a   Zhao, Shi ^a   Mao, Hong ^a   Zhou, Ling ^a   Wang, Zhong Jing ^a   Wang, Hong Xiang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Bone marrow stem cells; Diabetes mellitus; Hyperbaric oxygen therapy; Transplantation

Indexed keywords

ACARBOSE; C PEPTIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; INSULIN; METFORMIN; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERBARIC OXYGEN; INSULIN TREATMENT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE;

ADULT; BONE MARROW CELLS; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION;

EID: 82255173960     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.22.005     Document Type: Article

References (33)

1. Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care 2009; 32 Suppl 2: S151-S156.
2. Hanley SC, Austin E, Assouline-Thomas B, Kapeluto J, Blaichman J, Moosavi M, et al. {beta}-Cell mass dynamics and islet cell plasticity in human type 2 diabetes. Endocrinology 2010; 151: 1462-1472.
3. Gangaram-Panday ST, Faas MM, de Vos P. Towards stem-cell therapy in the endocrine pancreas. Trends Mol Med 2007; 13: 164-173.
4. Burt RK, Loh Y, Pearce W, Beohar N, Barr WG, Craig R, et al. Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA 2008; 299: 925-936.
5. Ciccocioppo R, Bernardo ME, Sgarella A, Maccario R, Avanzini MA, Ubezio C, et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut 2011; 60: 788-798.
6. Kroon E, Martinson LA, Kadoya K, Bang AG, Kelly OG, Eliazer S, et al. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol 2008; 26: 443-452.
7. Sun Y, Chen L, Hou XG, Hou WK, Dong JJ, Sun L, et al. Differentiation of bone marrow-derived mesenchymal stem cells from diabetic patients into insulin-producing cells in vitro. Chin Med J 2007; 120: 771-776.
8. Li Y, Zhang R, Qiao H, Zhang H, Wang Y, Yuan H, et al. Generation of insulin producing cells from PDX-1 gene-modified human mesenchymal stem cells. J Cell Physiol 2007; 211: 36-44.
9. Witt WT, Feghali-Bostwick C, Dai Y, Garcia-Ocana A, Feili-Hariri M. Autologous bone marrow-derived rat mesenchymal stem cells promote PDX-1 and insulin expression in the islets, alter T cell cytokine pattern and preserve regulatory T cells in the periphery and induce sustained normoglycemia. J Autoimmun 2009; 32: 33-42.
10. Gallagher KA, Goldstein LJ, Thom SR, Velazquez OC. Hyperbaric oxygen and bone marrow-derived endothelial progenitor cells in diabetic wound healing. Vascular 2006; 14: 328-337.
11. Milovanova TN, Moore JS, Hunt TK, Thom SR. Stem cells mobilization and vasculogenesis in vivo stimulated by lactic acid and hyperbaric oxygen. FASEB J 2007; 21: A381.
12. Milovanova TN, Bhopale VM, Sorokina EM, Moore JS, Hunt TK, Hauer-Jensen M, et al. Hyperbaric oxygen stimulates vasculogenic stem cell growth and differentiation in vivo. J Appl Physiol 2009; 106: 711-728.
13. Estrada EJ, Valacchi F, Nicora E, Brieva S, Esteve C, Echevarria L, et al. Combined treatment of intrapancreatic autologous bone marrow stem cells and hyperbaric oxygen in type 2 diabetes mellitus. Cell Transplant 2008; 17: 1295-1304.
14. Bhansali A, Upreti V, Khandelwal N, Marwaha N, Gupta V, Sachdeva N, et al. Efficacy of autologous bone marrow-derived stem cell transplantation in patients with type 2 diabetes mellitus. Stem Cells Dev 2009; 18: 1407-1416.
15. Lin Y, Yang X, Chen Z, Tan J, Zhong Q, Yang L, et al. Demonstration of the dorsal pancreatic artery by CTA to facilitate superselective arterial infusion of stem cells into the pancreas. Eur J Radiol 2011 Feb 10. Epub ahead of print.
16. Herzog EL, Chai L, Krause DS. Plasticity of marrow-derived stem cells. Blood 2003; 102: 3483-3493.
17. Butler AE, Huang A, Rao PN, Bhushan A, Hogan WJ, Rizza RA, et al. Hematopoietic stem cells derived from adult donors are not a source of pancreatic beta-cells in adult nondiabetic humans. Diabetes 2007; 56: 1810-1816.
18. Jarajapu YP, Grant MB. The promise of cell-based therapies for diabetic complications: challenges and solutions. Circ Res 2010; 106: 854-869.
19. Hess D, Li L, Martin M, Sakano S, Hill D, Strutt B, et al. Bone marrow-derived stem cells initiate pancreatic regeneration. Nat Biotechnol 2003; 21: 763-770.
20. Zorina TD, Subbotin VM, Bertera S, Alexander AM, Haluszczak C, Gambrell B, et al. Recovery of the endogenous beta cell function in the NOD model of autoimmune diabetes. Stem Cell 2003; 21: 377-388.
21. Oh SH, Muzzonigro TM, Bae SH, LaPlante JM, Hatch HM, Petersen BE. Adult bone marrow-derived cells trans-differentiating into insulin-producing cells for the treatment of type I diabetes. Lab Invest 2004; 84: 607-617.
22. Tang DQ, Cao LZ, Burkhardt BR, Xia CQ, Litherland SA, Atkinson MA, et al. In vivo and in vitro characterization of insulin-producing cells obtained from murine bone marrow. Diabetes 2004; 53: 1721-1732.
23. Lechner A, Yang YG, Blacken RA, Wang L, Nolan AL, Habener JF. No evidence for significant transdifferentiation of bone marrow into pancreatic beta cells in vivo. Diabetes 2004; 53: 616-623.
24. Abdi R, Fiorina P, Adra CN, Atkinson M, Sayegh MH. Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes 2008; 57: 1759-1767.
25. Madec AM, Mallone R, Afonso G, Abou ME, Mesnier A, Eljaafari A, et al. Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells. Diabetologia 2009; 52: 1391-1399.
26. Zanone MM, Favaro E, Miceli I, Grassi G, Camussi E, Caorsi C, et al. Human mesenchymal stem cells modulate cellular immune response to islet antigen glutamic acid decarboxylase in type 1 diabetes. J Clin Endocrinol Metab 2010; 95: 3788-3797.
27. Jurewicz M, Yang S, Augello A, Godwin JG, Moore RF, Azzi J, et al. Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes. Diabetes 2010; 59: 3139-3147.
28. Couri CE, Voltarelli JC. Stem cell therapy for type 1 diabetes mellitus: a review of recent clinical trials. Diabetol Metab Syndr 2009; 1: 19.
29. Vija L, Farge D, Gautier JF, Vexiau P, Dumitrache C, Bourgarit A, et al. Mesenchymal stem cells: Stem cell therapy perspectives for type 1 diabetes. Diabetes Metab 2009; 35: 85-93.
30. Urbán VS, Kiss J, Kovács J, Gócza E, Vas V, Monostori E, et al. Mesenchymal stem cells cooperate with bone marrow cells in therapy of diabetes. Stem Cells 2008; 26: 244-253.
31. Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F, et al. Autologous nonmyeloablative hemato-poietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007; 297: 1568-1576.
32. Couri CE, Oliveira MC, Stracieri AB, Moraes DA, Pieroni F, Barros GM, et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2009; 301: 1573-1579.
33. Taneera J, Rosengren A, Renstrom E, Nygren JM, Serup P, Rorsman P, et al. Failure of transplanted bone marrow cells to adopt a pancreatic beta-cell fate. Diabetes 2006; 55: 290-296.